Despite the many assays available to test for SARS-CoV-2 antibodies, a gold standard has not yet been established. In an article now published in PLOS ONE, CITF Testing Working Group members Dr. Anne-Claude Gingras from the University of Toronto, and Dr. Steven Drews from Canadian Blood Services, evaluate multiple testing platforms and the concordance [...]
A team of Vancouver investigators, led by Dr. Agatha Jassem of the British Columbia Centre for Disease Control (BCCDC) and partially funded by the CITF, assessed SARS-CoV-2 serological testing using two methods: finger pricking (dried blood spot or DBS) and traditional venipuncture (blood draw with a needle). Their observations, in pre-print and therefore not [...]
A group of researchers at Simon Fraser University, the BC Centre for Excellence in HIV/AIDS and Providence Health care led by CITF-funded researcher Dr. Zabrina Brumme have developed a method to quantify SARS-CoV-2 virus levels in human biological specimens using a technique called droplet digital RT-PCR (RT-ddPCR). Key points: This method can be [...]
A recent preprint, not yet peer reviewed, by CITF Testing Working Group members Dr. Anne-Claude Gingras from University of Toronto, and Dr. Steven Drews from Canadian Blood Services, compared multiple assays and concluded ‘Made-in-Canada’ ones performed well. Blood samples were collected through Canadian Blood Services between April and September 2020. A total of [...]
Many Canadian serosurveys have opted to use dried blood spot (DBS) tests as a practical means to study population-level SARS-CoV-2 prevalence. Tens of thousands of Canadians have received DBS kits in the mail. In this preprint, not yet peer-reviewed, researchers, including several CITF members, set out to determine which of the available DBS assays [...]
As the pandemic continues to evolve, it has become increasingly important to systematically adapt testing capacities to detect all variants of concern. In a recently published article, CITF-funded researcher Dr. Marc Romney and his team at the University of British Columbia proposed a new testing strategy that can rapidly detect circulating variants, and which [...]
Researchers from Public Health Ontario and the University of Toronto found that there was a drop in the number of samples with detectable antibodies over time using the Abbott Architect SARS-CoV-2 IgG assay, but not when using the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test. The study provides evidence that there exists potentially significant variability in assays, which may give the impression of waning protection against COVID infection.